...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Tumour biology : >Concurrent chemoradiotherapy with or without adjuvant chemotherapy in intermediate and locoregionally advanced nasopharyngeal carcinoma
【24h】

Concurrent chemoradiotherapy with or without adjuvant chemotherapy in intermediate and locoregionally advanced nasopharyngeal carcinoma

机译：中晚期局部鼻咽癌的同时放化疗联合或不联合辅助化疗

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Concurrent chemoradiotherapy (CCRT) showed a significant improvement in disease control and clinical outcome in patients with intermediate and locoregionally advanced nasopharyngeal carcinoma (NPC) (stage II, III and IVA+B). However, there has been debate about the contribution and application of additional adjuvant chemotherapy (AC) to a CCRT regime. This study aims to evaluate the additional value of AC in the treatment of intermediate and locally advanced NPC with regard to toxicity and clinical outcomes. A total of 189 patients with American Joint Committee on Cancer (AJCC) stage II to stage IVB NPC were retrospectively identified. Patient characteristics, toxicity, compliance with treatment and clinical outcomes, including response to treatment, overall survival (OS), progression-free survival (PFS), relapse-free survival (RFS), freedom from local recurrence (FLR) and freedom from distant metastasis (FDM), were analyzed. The overall response rate of CCRT and CCRT/AC groups was 97.92 % and 97.83 %, respectively (P = 0.643). The 5-year OS rate was 68.2 % in the CCRT group and 75.9 % in the CCRT/AC group (P = 0.53). The 5-year PFS rate was 66.7 % and 71.4 % in CCRT and CCRT/AC groups, respectively (P = 0.96). This study showed no evidence of an additional value of AC in CCRT treatment in disease control and clinical outcomes in patients with locally advanced NPC in endemic regions. Moreover, three additional cycles of AC after CCRT appeared to be poorly tolerated in patients. Therefore, AC should not be routinely used for treatment, although clinical trials may be justified.
机译：同期放化疗（CCRT）显示中，局部区域晚期鼻咽癌（NPC）（II，III和IVA + B期）患者在疾病控制和临床结果方面有显着改善。但是，关于辅助化疗（AC）对CCRT方案的贡献和应用一直存在争议。这项研究旨在评估在中度和局部晚期NPC的毒性和临床疗效方面AC的附加价值。回顾性分析了189例美国癌症联合委员会（AJCC）II期至IVB期NPC患者。患者特征，毒性，对治疗的依从性和临床结果，包括对治疗的反应，总生存期（OS），无进展生存期（PFS），无复发生存期（RFS），无局部复发（FLR）和无远处转移转移（FDM），进行了分析。 CCRT和CCRT / AC组的总缓解率分别为97.92％和97.83％（P = 0.643）。 CCRT组的5年OS率为68.2％，CCRT / AC组为75.9％（P = 0.53）。 CCRT和CCRT / AC组的5年PFS率分别为66.7％和71.4％（P = 0.96）。这项研究表明，没有证据表明在地方病晚期局部NPC患者的CCRT治疗中，AC在疾病控制和临床结局方面具有附加价值。此外，CCRT后AC的另外三个周期似乎对患者的耐受性较差。因此，尽管临床试验可能是合理的，但是不应将AC常规用于治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号